UK Medical Device Regulations: UKCA Marking and MHRA Clinical Investigation Requirements
- Sharan Murugan
- 19 hours ago
- 4 min read
The United Kingdom’s medical device regulatory system has changed significantly following Brexit. Medical device manufacturers that previously relied mainly on European Union regulations must now also understand UK-specific regulatory requirements for placing devices on the Great Britain market and conducting clinical investigations in the UK.
To help manufacturers, sponsors, and regulatory professionals understand these expectations, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has published detailed guidance
These guidance documents explain how manufacturers can legally market medical devices in Great Britain and how sponsors should notify MHRA before conducting certain clinical investigations involving medical devices.
What is the UKCA Mark?
The UKCA mark stands for:
UK Conformity Assessed
It is the conformity marking used for products placed on the market in:
England
Scotland
Wales
The UKCA mark shows that a medical device complies with applicable UK requirements related to:
Safety
Performance
Quality
Intended use
Risk management
Without proper conformity assessment and regulatory compliance, manufacturers generally cannot legally place applicable medical devices on the Great Britain market.
Why Was UKCA Introduced?
Before Brexit, medical devices sold in the UK mainly used CE marking under EU legislation.
After Brexit:
Great Britain introduced UKCA marking
Northern Ireland continued following separate arrangements linked to EU rules
Manufacturers now need to understand different regulatory systems depending on the market where the device will be sold
The UKCA system was introduced to establish an independent UK regulatory framework while continuing to maintain patient safety and regulatory oversight.
For manufacturers selling products globally, this means they may now need to manage:
UKCA requirements for Great Britain
CE marking requirements for Europe
Additional Northern Ireland requirements
This has increased the importance of regulatory planning and compliance management.
Difference Between UKCA and CE Marking
One of the most important areas manufacturers need to understand is the difference between UKCA marking and CE marking.
Currently:
UKCA marking applies to Great Britain
CE marking applies to the European Union
Northern Ireland continues recognizing CE marking under separate arrangements
This means manufacturers may need different certifications depending on where the device will be marketed.
For example:
A device sold in Germany requires CE marking
A device sold in England may require UKCA marking
A device sold in Northern Ireland may require CE marking or CE UKNI marking
This regulatory separation has made market access planning more complex for medical device companies.
Types of Medical Devices Covered
The UKCA framework applies to different categories of medical devices, including:
General medical devices
Active implantable medical devices
In vitro diagnostic medical devices (IVDs)
Different conformity assessment pathways apply depending on:
Device classification
Intended use
Device complexity
Risk level
Higher-risk devices generally require more detailed review and regulatory oversight.
For example:
Low-risk devices may follow simpler conformity routes
High-risk implantable devices may require extensive technical documentation and external review
The level of regulatory review increases as patient risk increases.
Understanding Conformity Assessment
Conformity assessment is the process used to evaluate whether a medical device meets applicable regulatory and technical requirements.
This process helps determine whether the device satisfies expectations related to:
Device safety
Clinical performance
Product quality
Manufacturing controls
Risk management
Labeling requirements
Manufacturers are responsible for preparing technical documentation that demonstrates compliance with UK regulatory requirements.
Depending on the device classification, manufacturers may either:
Self-declare conformity for some lower-risk devices
Undergo independent review by a UK Approved Body for higher-risk devices
The conformity assessment process is an important part of ensuring that medical devices placed on the market are safe and perform as intended.
Their role is to verify that the device consistently meets applicable UK regulatory requirements.
If the device successfully passes the conformity assessment process, the manufacturer may apply the UKCA mark and market the device in Great Britain.
For many medium- and high-risk devices, review by a UK Approved Body is mandatory before commercialization.
What is a Clinical Investigation?
A clinical investigation is a study involving a medical device used on human participants.
These studies are conducted to evaluate:
Device safety
Clinical performance
Effectiveness
Usability
Benefit-risk profile
Clinical investigations are especially important for:
New technologies
Innovative devices
Higher-risk devices
Devices with new intended uses
Products lacking sufficient clinical evidence
The evidence generated during these studies may later support:
UKCA conformity assessment
Regulatory approval
Market access decisions
Clinical evidence plays an increasingly important role in modern medical device regulation.
Purpose of the Clinical Investigation Guidance
The MHRA guidance explains how sponsors should notify the agency before conducting certain clinical investigations involving medical devices.
The guidance provides information regarding:
Submission procedures
Required documentation
Sponsor obligations
Safety monitoring
Reporting requirements
Ethical review expectations
The overall goal is to help ensure that clinical investigations are conducted safely and ethically while complying with UK regulations.
When Notification to MHRA Is Required
According to the guidance, sponsors generally need to notify MHRA before conducting investigations involving:
Non-UKCA marked devices
Non-CE marked devices
Devices used outside their approved intended purpose
The notification should usually be submitted:
At least 60 days before starting the clinical investigation.
This allows MHRA time to review:
Device safety information
Participant risks
Study design
Monitoring procedures
Ethical considerations
The agency may request additional information if needed before the investigation begins.
Information Required for MHRA Notification
Sponsors are generally expected to provide several important documents during the notification process.
These may include:
Clinical investigation plans or protocols
Device descriptions
Risk analysis documentation
Investigator brochures
Informed consent forms
Participant information sheets
Safety monitoring procedures
The quality and completeness of these submissions are important because they support MHRA’s assessment of participant safety and study appropriateness.
Incomplete submissions may delay the review process.
Sponsor Responsibilities During Clinical Investigations
The guidance explains that sponsors have several important responsibilities during clinical investigations.
Sponsors are responsible for ensuring:
Participant safety
Ethical study conduct
Proper monitoring procedures
Regulatory compliance
Accurate reporting
Documentation management
Sponsors must also ensure that investigators are properly trained and qualified.
In addition, sponsors should maintain systems for monitoring adverse events and device deficiencies throughout the study.
Together, these guidance documents strengthen the UK’s evolving medical device regulatory framework and For more details, click the references below
Comments